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The continuously increasing cost of the US healthcare system has received significant attention. Central
to the ideas aimed at curbing this trend is the use of technology, in the form of the mandate to implement
electronic health records (EHRs). EHRs consist of patient information such as demographics, medications,
laboratory test results, diagnosis codes and procedures. Mining EHRs could lead to improvement in patient
health management as EHRs contain detailed information related to disease prognosis for large patient
populations. In this manuscript, we provide a structured and comprehensive overview of data mining
techniques for modeling EHR data. We first provide a detailed understanding of the major application areas
to which EHR mining has been applied and then discuss the nature of EHR data and its accompanying
challenges. Next, we describe major approaches used for EHR mining, the metrics associated with EHRs,
and the various study designs. With this foundation, we then provide a systematic and methodological
organization of existing data mining techniques used to model EHRs and discuss ideas for future research.
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1. Introduction
Numerous recent studies have found that the health care system in the United
States is the most expensive in the world, yet it is trailing behind most advanced
economies in quality [Schuster et al. 1998]. The cost of health care is steadily rising
both in absolute terms and also as a percentage of the GDP, soon reaching unsustain-
able levels [Levit et al. 2003]. To curb this trend, the US government has put several
initiatives in place, aiming to simultaneously improve care quality and decrease its
cost. Many believe that advanced analytics holds the key to achieving these opposing
goals.
The earliest of these initiatives was the mandate for health care providers to im-
plement electronic health record (EHR) systems. While the primary goal of the EHR
is to documenting patients’ care for reimbursement, a secondary use of the accumu-
lated data is often to serve as a research platform. This EHR data coupled with other
health-related data provides the platform on which advanced analytics can be built.
The motivation for advanced analytics comes from another government mandate
that transforms the current fee-for-service payment model to a new model based on
population health management. Under the new model, primary care providers are
responsible for managing entire patient populations with their payments tied to care
quality. Since care providers are no longer paid for services rendered, but rather for
the outcomes of the service, they are incentivized to increase their efficiency through
implementing better care practices, thus creating an opportunity for analytics.
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With ample data in EHR and a motivation for analytics, we need an outlet for
the findings. The learning health care system, a concept embraced by the Institute
of Medicine, is an adaptive system, in which “best practices seamlessly embedded in
the delivery process and new knowledge captured as an integral by-product of the de-
livery experience”. In this context, advanced analytics, clinical data mining included,
will without doubt play an important role in extracting new knowledge, quantifying
the effects of changes in care delivery and possibly forming best-practice guidelines.
The learning health care system initiative is accompanied by other symbiotic initia-
tives that are likely to influence the medicine of the future. Precision medicine is one
of them. It is a model, where treatment is tailored to each individual patient. While
precision medicine has a large genomic component, finding increasingly specific treat-
ments from EHR data is another avenue, one that naturally fits into today’s practice
framework.
The predominant medical practice framework today is evidence-based
medicine[Sackett 2000]. At the heart of evidence-based practice lies a large knowledge
base of best practice recommendations that have been put forth by committees of
well-established care providers and (ideally) validated through randomized clinical
trials. These best practice recommendations, if followed, can enable providers to
increase their efficiency and reduce waste.
The traditional vehicle for evidence creation is the randomized clinical trial
[Matthews 2006]. Randomized clinical trials are considered the gold standard for evi-
dence creation, but the body of evidence they create is woefully incomplete. Trials are
very expensive to conduct, thus they are relegated to a confirmatory role; in particular
they are impractical for exploration.
Clinical data mining on top of EHR data offers a solution which makes it comple-
mentary to clinical trials. With EHRs tracking entire populations over extended time
periods, EHR data have large sample sizes and potentially long follow-up times pos-
sibly allowing us to test a large number of exploratory hypotheses. Through flexible
modeling, EHR data can provide useful information to facilitate clinical decision sup-
port, to analyze condition-specific clinical process outcomes and to improve team-based
population care beyond the tradional clinical encounters.
With all three ingredients of success for data mining—data, motivation and outlets
for results—having come together, we believe that an explosive growth in the adoption
of clinical data mining is imminent. Unfortunately, EHR data poses unique challenges
that data mining has previously not faced. Before reviewing existing work on clinical
data mining involving EHR data, in this survey, we summarize background knowledge
on study design, the characteristics and challenges of EHR data, and techniques devel-
oped by other disciplines to overcome these challenges. We hope that our survey will
prove to be a useful tool that helps turning the challenges that EHR data poses into
a wave of innovation in data mining that will unlock the immense potential of clinical
data mining.
Overview: Our survey is structured as a reflection of the steps carried out in clinical
research. Our first step is to frame a clinical problem that we wish to study. In Section
2, we give the reader a flavor of the clinical questions by providing descriptions of sev-
eral applications starting from the simplest clinical questions and progressing towards
more complex analytics tasks.
Once the clinical question has been defined, data modeling starts. In Section 3, we
provide a detailed description of EHR data, its elements and characteristics. As we
discussed earlier, the primary function of EHR data was not to serve as a research
platforms thus it poses numerous challenges which we describe in Section 4.
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As the next step in the analysis process, we select a metric of interest. EHR data
is multidimensional, multimodal irregular time series data with many potential out-
comes. A rich array of metrics can be designed and measured on such data, but only
a handful are well defined, understood and accepted in the health sciences research
community. In Section 5, we describe the most commonly used metrics, those that the
community tracks and uses to inform policy decisions.
EHR data is a collection of data tables, a format that data mining algorithms cannot
directly operate on. These tables need to be summarized into a data matrix in a manner
that allows us to answer our clinical question or compute our metric of interest. This
process is known as study design and in Section 6, we will introduce the study designs
that are most suitable for mining EHR data.
At this point in the analysis, we have a data matrix that we could run our data min-
ing algorithms on, but doing so has the potential to produce misleading results. EHR
data still has some challenges that could seriously affect or invalidate our analysis. Ex-
amples of such challenges include situations when a patient drops out before the study
concludes (referred to as censoring); patient populations whose members are in widely
different states of health and thus outcomes are not comparable across these patients;
and a highly variable number of per-patient observations. In Section 7, we introduce
higher level frameworks that have been developed to overcome such challenges.
Data mining algorithms can operate within these frameworks or can be adapted to
fit into these frameworks. In section 8, we provide a comprehensive overview of how
data mining methods have been applied to mine EHR data and how the data mining
methods have contributed to the clinical research carried out in various applications
areas, that we introduced in Section 2.
In Section 9, we present the current state of clinical data mining and identify areas
that are well covered by existing techniques and areas that require the development
of new techniques and finally, while Section 10 concludes with the discussion of future
of EHR data mining.
Although health care data mining is still in its infancy, in this survey we have cov-
ered several hundred scientific articles in this area. We describe the required back-
ground knowledge and lay out the principles that allow us to organize this vast body
of research. Due to page limitations, we have focused the main article on the sequence
of steps researchers need to take to complete an EHR-based data mining analysis
citing only a small number of representative examples. Accompanying supplemental
material contains a more comprehensive listing of papers descibing application of data
mining to EHR data.
Scope: The primary purpose of this survey is to provide the necessary background
and an overview of the existing literature of mining structured EHR data towards
answering clinical questions. Areas, such as bioinformatics, computational biology
and translational bioinformatics, which are indispensable to the future of medicine,
but utilize their own specific techniques and deserve surveys of their own right; we
decided to exclude them from the scope of this survey. We also excluded medical
image analysis and techniques related to mining semi-structured or unstructured
data through Natural Language Processing (NLP) and information retrieval because
the technical challenges they pose are quite different from the challenges we face in
mining structured EHR data.
2. Application Areas
An appropriate place to start our discussion of clinical data mining is to describe
some clinical questions that data mining can help answer. The fundamental question
of medicine is to decide on the treatment that is most suitable and effective for a par-
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ticular patient and data mining has the potential to help address this question in
numerous ways.
In this section, we present a sequence of increasingly complex clinical applications,
starting with the simplest epidemiological questions, continuing with common clinical
research tasks such as automatic identification of study cohorts, risk prediction and
risk factor discovery, all the way to complex applications such as discovering knowledge
related to best clinical practices from data.
2.1. Understanding the Natural History of Disease
The most basic epidemiological inquiries are not data mining problems per se, they
are concerned with questions like: How many patients are diagnosed with a condition
of interest? What is the incidence rate and symptoms of a disease? What is the natural
history of progression of the disease, or in other words, what are the symptoms and
implications of any clinical condition of interest?
Studying the sequences of diseases clearly enters the realm of data mining and it has
been applied to studying the progression of a patient’s medical state over time, which
is also known as the patient’s medical trajectory. Examples of such trajectories are the
progression of the patient from a healthy state through conditions like hyperlipidemia
(high cholesterol), hypertension (high blood pressure), diabetes towards diabetes as-
sociated complications (e.g. amputation, severe paralysis or death). Often, multiple
trajectories lead to the same outcome. For example, consider an outcome such as mor-
tality. In this case, a patient might die due to kidney complications, cardio-vascular
complications or peripheral complications. Even though the outcome (mortality in this
case) is the same, disease progression paths leading to the outcome might be different.
Research studies have demonstrated that different trajectories can have significantly
different associated risks for the same outcome [Oh et al 2016; Yadav et al. 2015b].
Studying such varying trajectories can lead to the development of tailored treatments,
discovery of biomarkers or the development of novel risk estimation indices.
The number of patients suffering from two or more chronic diseases, a condition re-
ferred to as multimorbidity, has increased substantially in the last ten years and mul-
timorbidity is the norm with elderly patients [Mercer et al 2009]. Diseases co-occur
due to coincidence, causal relationships and common underlying risk factors includ-
ing frailty. The coexistence of multiple chronic diseases increases the risk of mortality,
physical function, decreases quality of life and is also associated with longer hospital
stays, increased risk of postoperative complications and a higher overall healthcare
utilization [Wolff 2002]. When diseases co-occur, it is desirable to treat them simulta-
neously. Comorbidity analysis is the process of exploring and analyzing relationships
among diseases and it is the key to understanding multimorbidity and tailoring treat-
ment accordingly. An example of multimorbidity is type 2 diabetes mellitus (T2DM)
which is often accompanied by hypertension, hyperlipidemia and impaired fasting glu-
cose (IFG); these latter three conditions are comorbid to T2DM. Further, analyzing the
comorbidities and discovering the relationships among them can lead to the modifica-
tion of existing comorbidity scores (such as Charlson index) or to the development of
novel ones.
2.2. Cohort Identification
Once we understand these fundamentals, we can try answering more advanced
questions. To this end, we may need to assemble a cohort (group) of patients, some
of whom are extremely likely to have the disease of interest (cases) and others who
most likely do not (controls). This can be achieved through phenotyping algorithms,
either hand-crafted or machine learned. Phenotyping algorithms characterize the dis-
ease in terms of patient characteristics observable from the EHR data and classify
patients as likely having the disease, likely not having the disease, or disease status is
uncertain [Kirby et al. 2016].
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Traditionally, cohort identification was carried out through chart reviews, where
nurse abstractors have painstakingly reviewed patients’ medical records to identify
whether each patient satisfies the criteria for inclusion into the cohort. However the
scale enabled by EHRs renders manual chart review impractical. Instead, electronic
phenotyping algorithms are applied, with manual chart review relegated to spot-
checking. Cohort identification has been widely used in various clinical research stud-
ies and biomedical applications, forming the platform on which future studies can be
carried out in areas such as pharmacovigilance, predicting complications, and quanti-
fying the effect of interventions.
A phenotype is defined as a biochemical or physical trait of an organism, such as a
disease, physical characteristic, or blood type. Examples of phenotypes in EHRs are
clinical conditions, characteristics or sets of clinical features that can be determined
solely from the EHR data. Such techniques are useful for identifying patients or pop-
ulations with a given clinical characteristic from EHRs using data that are routinely
collected and stored in disease registries or claims data. Phenotyping queries used for
cohort identification can be used at different sites in a similar fashion in order to en-
sure that populations identified across healthcare organizations have similar clinical
state. Phenotypic definitions can also be used for direct identification of cohorts based
on risk factors, clinical or medical characteristics, and complications, thereby allow-
ing clinicians to improve the overall healthcare of a patient. For a detailed review of
phenotyping, the reader is referred to Shivade et al. [Shivade et al. 2014].
2.3. Risk Prediction/Biomarker Discovery
With a cohort in hand, we can build risk models, opening up a wide range of opportu-
nities for data mining. An example of a successful risk model is the Framingham heart
score which estimates patients’ risk of cardio-vascular mortality. In recent years, age-
adjusted cardio-vascular deaths have reduced by half in developed countries. Much of
this success is attributed to the Framingham Heart Study, which helped identify the
key risk factors of cardio-vascular mortality [Bitton and Gaziano 2010]. This success
can potentially be replicated in other areas of medicine.
Such models can predict the risk of developing a disease, e.g. estimating the prob-
ability of developing a condition of interest in 5 years (risk prediction). Such analysis
is often performed to identify high risk individuals, and facilitate the design of their
treatment plans [Ng et al. 2014]. Interventions prescribed by risk analyses can lead to
improvement in a patient’s health, thereby preventing the patient from progressing to
advanced complications.
In some cases, predicting the patient’s risk of progression is secondary to under-
standing the underlying risk factors. Risk models can provide information about the
importance of risk factors. Risk prediction also provides the opportunity to identify
significant indicators of a biological state or condition. In simple terms, a biomarker is
defined as a set of measurable quantities that can serve as an indicator of a patient’s
health. Biomarkers offer a succinct summary of the patient’s state with respect to a
medical condition. Rather than having to analyze the thousands of variables present
in an EHR, it can be sufficient to focus on relatively few biomarkers to paint a rea-
sonably accurate picture of the patient’s overall health. Over the years, biomarkers
have found numerous applications. For example, abnormal hemoglobin A1C (measure
of blood sugar) is a biomarker for Type-2 Diabetes Mellitus (T2DM) and high choles-
terol is a biomarker for being at risk of cardio-vascular complications. Similarly, there
are certain biomarkers, which are common across many diseases. For example, age is
by far the most common biomarker. It indicates that as a person ages, his or her risk
to acquire certain diseases (e.g T2DM, cardio-vascular complications and kidney com-
plications) increases significantly. EHRs provide a platform to identify, analyze and
explore biomarkers for multiple diseases.
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2.4. Quantifying the effect of Intervention
Interventions are often drug therapies or surgeries, but can also include recommen-
dations for life style changes and/or patient education. Choosing the optimal treatment
for a patient requires us to be able to estimate the effect of the possible interventions.
Specialized data mining methods such as uplift modeling or statistical techniques in
combination with causal analysis can be used to quantify the effects of interventions.
The longitudinal aspect of EHRs provides an opportunity to analyze the effects of
intervention for longer period of time across larger cohorts. It also provides clinicians
with a platform to analyze whether the interventions have any accompanying adverse
effects. Moreover, EHRs provide a platform to analyze whether interventions vary
across cohorts based on demographics attributes such as gender, age, ethnic make-up,
socio-economic status, etc.
2.5. Constructing Evidence Based Guidelines
Once the effect of a treatment has been proven, this knowledge can be codified
into and disseminated as clinical practice guidelines. Evidence-based clinical prac-
tice guidelines are considered the cornerstone of modern medicine, and they provide
guidance on the optimal treatment under a particular set of conditions based on epi-
demiological evidence.
Clinical guidelines can be defined as standardized specifications and procedures usu-
ally used to improve or take care of a patient in specific clinical circumstances [Field et
al. 1992]. Evidence based guidelines try to guide decision making by identifying best
clinical practices, that are meant to improve the quality of patient care [Barretto et al.
2003]. They help clinicians make sound decisions by presenting up to date informa-
tion about best practices for treating patients in a particular medical state including
expected outcomes and recommended follow up interval. For example, the American
Diabetes Association (ADA) guidelines for diabetes consist of recommendations for di-
agnosing the condition (e.g. a patient is considered diabetic if his hemoglobin A1c is
greater than 6.5), controlling the disease (patient is under control if his A1c < 6.5 and
his systolic blood pressure < 140 mmHg) and prescribing interventions (lifestyle mod-
ification and therapeutic interventions, as well). These guidelines are often regarded
as the cornerstone of modern healthcare management.
2.6. Adverse Event Detection
This term describes the detrimental effect of patient medical state as a result of
medical care. Examples include infection acquired during the treatment of a differ-
ent condition, such as surgical site infection. According to a 2010 report by the In-
spector General of the Department of Health and Human Service, 13.5% of hospi-
talized Medicare beneficiaries have experienced adverse events, costing Medicare an
estimated $340 million in Oct. 2008 alone. An estimated 1.5% of beneficiaries, which
corresponds to 15,000 patients per month, experienced an adverse event that lead to
their deaths [Levinson and General 2010]. Detecting and learning to prevent adverse
events is clearly a major opportunity for advanced analytics, as 44% of these adverse
event were deemed avoidable.
Another related opportunity is the identification of potentially preventable events.
Potentially preventable events are patient encounters (emergency and urgent care vis-
its, or hospitalization) that could have been avoided by appropriate outpatient treat-
ment and adequate compliance with those treatments. The Agency for Healthcare Re-
search and Quality (AHRQ) reports that potentially preventable events are decreasing,
but still nearly 4 million hospitalizations in the US were avoidable in 2010, if the pa-
tient had received proper care [Torio et al. 2006]. Costs related to these preventable
hospitalizations totaled $31.9 billion in 2010.
Adverse events can often be linked to drugs. Adverse drug events account for 1 in 3
hospital adverse events and in the outpatient setting, adverse drug events cause 3.5
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million physician visits, 1 million emergency room visits and 125,00 hospitalizations
each year [Torio et al. 2006]. Although drugs are tested for any potential adverse effects
before they are released for widespread use, often test cohorts are small with short ob-
servation periods. Several agencies conduct research on detecting adverse drug reac-
tions: U.S. Food and Drug Administration with its adverse event reporting system, the
European Medicines Agency, and the World Health Organization, which maintains an
international adverse reaction database. Despite these efforts, all these agencies suf-
fer from underreporting and biased analyses of adverse drug reactions. EHRs provide
a new platform to improve and complement drug safety surveillance strategies.
3. Nature of EHR Data
One motivation behind the federal mandate for EHRs was to document patients’
state of health over time and the therapeutic interventions to which these pa-
tients were subjected. EHRs store this information in structured (databases), semi-
structured (flow sheets) and unstructured formats (clinical notes). The format of the
information greatly affects the ease of access and quality of the data, and thus has
substantial impact on the downstream data mining.
3.1. Structured Data
From the viewpoint of healthcare analytics, retrieving structured data is the most
straightforward. Structured data is stored in database tables with a fixed schema de-
signed by the EHR vendor. The most commonly used information, such as demographic
information (e.g. birth date, race, ethnicity), encounters (e.g. admission and discharge
data), diagnosis codes (historic and current), procedure codes, laboratory results, med-
ications, allergies, social information (e.g. tobacco usage) and some vital signs (blood
pressure, pulse, weight, height) are all stored in structured tables. This kind of infor-
mation is common across providers and not specific to any clinical specialty. Thus the
use and format of this information is well handled by the EHR vendors. This allows
such information to be stored in structured data tables with apriori defined layouts
(schema). Fixed schemas enable high performance (rapid access to data) and stan-
dardization: the schemas for these tables are very similar if not identical across instal-
lations by the same EHR vendor, requiring very little (if any) site-specific knowledge
from users. This quasi-standardization of fields also greatly helps information retrieval
for analytic purposes.
Storing all information in EHRs as structured elements, however, is impractical: it
would require anticipation of all possible data elements (e.g. metrics whose usefulness
we do not yet appreciate) and would result in a level of complexity that would ren-
der the EHR system unusable. However, there is a need for storing information that
does not readily fit into the admittedly rigid schema of the structured tables. For ex-
ample, clinicians often write notes about patient’s symptoms based on their previous
experiences, which is hard to standardize a priori.
3.2. Unstructured Data
Among the three formats, clinical notes (unstructured data) offer maximal flexibility.
Clinical notes mostly store narrative data (free text). Many types of clinical notes are
in existence, and the information that resides in them depends on the type of note (e.g.
radiology report, surgical note, discharge notes). These clinical notes can contain infor-
mation regarding a patient’s medical history (diseases as well as interventions), famil-
ial history of diseases, environmental exposures and lifestyle data all reside in clinical
notes. Natural language processing (NLP) tools and techniques have been widely used
to extract knowledge from EHR data.
Clinical notes such as admission, treatment and discharge summaries store valu-
able medical information about the patient, but these clinical notes are very subjective
to the doctor or the nurse writing them, and lack a common structure or framework.
These clinical notes also have grammatical errors, short phrases, abbreviations, local
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dialects and misspelled words. Considerable data processing needs to be conducted on
these clinical notes such as spelling correction, word sense disambiguation, contextual
feature detection, extraction of diagnosis codes from clinical text, and adverse events
surveillance. This makes deriving information about patient characteristics from clini-
cal notes a computationally challenging task that requires the most sophisticated NLP
tools and techniques. For a detailed review on application of NLP to clinical decision
support, the reader is referred to [Demner-Fushman et al. 2009]
3.3. Flowsheets
In between the two extremes (structured tables and unstructured clinical notes) lies
the (semi-structured) flow sheet format. This format is most reminiscent of resource
description files (RDF), consisting of name, value and time stamp triplets. Typically,
the “name” field stores the name of the measure and the “value” field contains the
actual measurements: e.g. the name is “arterial blood pressure” and the value is 145
Hgmm. This format is more flexible than the structured tables, since the user can
define new metric through the name field; the set of metrics is not restricted to those
anticipated by the EHR vendor. Flow sheets are similar to structured data in the sense
that the value field is either a quantitative measure (e.g. blood pressure) or typically a
restricted set of values. For instance, the American Society of Anesthesiologists (ASA)
physical status takes values of “mild systemic disease”,“healthy”, “severe systemic dis-
ease”,“moribund” or “severe life-threatening systemic disease”.
Flow sheets offer expandability to EHR systems and thus have found numerous
uses, becoming the only or most convenient data repository for many applications.
Possibly the most important use for flow sheets is that they provide detailed infor-
mation about specialty care. For example, information related to a patient’s asthma
care plans can be stored in flow sheets or they may store various diabetes-related
non-standard (or not-yet-standard) metrics for a diabetes clinic. In addition, they
may provide additional details regarding how a particular measure was obtained
(blood pressure taken while the patient was lying flat) and can also be used to store
automated sensor data (e.g. pulse and blood oxygen levels every few minutes in
an intensive care unit). Further, flow sheets can be used to pull together related
measurements such as quality indicators.
4. Data-Related Challenges
EHR data as a research platform poses numerous challenges. Many of those chal-
lenges are not specific to EHR data and are also frequently encountered in other do-
mains: noise, high dimensionality, sparseness, non-linear relationships among data
elements, complicated dependencies between variables. Less frequent, but still not un-
common elsewhere, are issues related to data integration across multiple sites (medical
providers) and / or multiple types of data sets (e.g. clinical vs. claim data). As in other
domains, it is also important to incorporate domain knowledge, including knowledge
about the relationships. For example, the blood pressure of a patient on medication for
hypertension needs to be interpreted in that context.
In this section, we describe a number of challenges, common in health care but less
studied in other areas, that put the external validity of the analysis at risk. Many of
these relate to issues stemming from data missing for various reasons.
In the following subsections, we will discuss these various issues in greater detail.
4.1. Censored Data
By censored data, we refer to the situation where a patient’s state is only observable
during a certain period of time; or conversely, when potentially interesting events fall
outside the observation period and are hence unobservable. In case of left censored
data, patients experience events of interest prior to the start of the study; in case
of right censored data, potentially interesting events are unobservable because they
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happened to the patient after he dropped out of the study or after the conclusion of the
study. In case of interval censored data, information is only available of the data being
within a certain limit. Studies can be either left, right or interval censored. Censoring
can lead to loss of crucial information about the patient’s health. For example, for
the right censored patient, there is neither an easy way to determine whether the
patient is alive or dead nor to measure the efficacy of the treatment the patient was
undergoing.
4.2. Fragmentation
Fragmentation is a lack of data sharing across providers. Fragmentation typically
occurs when patients visit multiple healthcare providers seeking specialty care, ex-
pert advice or second opinions. In such scenarios, all healthcare provider involved only
have partial information about the patient’s medical history. Integrating data across
multiple healthcare providers poses several challenges. Some of these are operational
challenges, such as communication between different EHR systems such as General
Electric (GE) or Epic, requiring a common language to transfer information into HL-7
(common protocol), which cannot capture all nuances. Even when multiple sites use
the same EHR format, their treatment policies may differ, flowsheets may differ and
thus their definitions of nuanced concepts may differ. For example, fasting and ran-
dom glucose measurements are not distinguished by lab codes and different sites can
apply different methods to distinguish the two. Other challenges involve the (lack of)
willingness of competing providers to share data.
4.3. Irregular Time Series Data
Beside our inability to make observations before the study period starts or after it
concludes, the most striking characteristic of the EHRs data is the irregularity of the
patient visits. While recommended frequency of visits may exist, many patients do not
actually follow these recommendations. For example, as per the American Diabetes
Association (ADA) guidelines, A1C test must be performed at least two times a year
for patients who are meeting treatment goals and have stable glycemic control.
Further, the frequency at which information is collected varies. While vitals are col-
lected at every visit, certain laboratories tests are ordered annually, and other tests
are performed only as needed. This difference in the frequency of collection of medi-
cal information leads to irregular longitudinal data. Analyzing regular time series is a
well-studied problem in data mining, but application of these techniques to EHR-type
irregular time series is very challenging.
4.4. Other Sources of Missing Data
Diagnosis codes might also be missing due to reimbursement rules. Different prob-
lems, comorbidities or complications have different reimbursement rates: depending
upon the complications, the same procedure may have different costs and thus re-
sult in increased or decreased reimbursements. Due to these financial constraints only
some of the problems related to the primary cause of the visit, are used to generate
billing codes (ICD codes are used to represent these problems in billing records). This
leads to biases in ICD-9 codes, as the billing codes might not be a true representation
of the actual medical state of the patient.
Diagnosis codes can also be missing due to changes in disease definitions and up-
dates to the ICD-10 codes. For example, pre-diabetes did not have a corresponding
ICD-10 code until 2000. The introduction of new and the periodic updates to existing
ICD codes leads to further complications such as a lack of a clear mapping from the
old revision to the new and subsequently, to inconsistent research findings.
Another largely unobservable source of missing information lies in patient confor-
mance with prescriptions and other intervention, such as lifestyle change recommen-
dations. The orders table in an EHR indicates that the physician prescribed a medica-
tion, but in most cases we do not know whether the patient actually took the medica-
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tion. This situation is referred to as Intent to Treat. In the case of the lifestyle change,
we may not even have documentation that the patient followed this advice.
A unique aspect of missing data in clinical analytics is that whether the data is miss-
ing or not can be predictive. When a physician orders a test, he usually suspects that
the patient may suffer from the corresponding condition. Conversely, by not ordering
certain tests, the clinician suggests that corresponding medical conditions are absent.
For example, no bacterial panel being ordered likely indicates that the patient is not
suffering from any infection.
4.5. Biases and Confounding Effects
Studies performed using EHRs often have biases and confounding effects [Moher et
al. 1998]. Biases might arise due to multiple reasons. For example, in a cohort study,
there might be significant differences in baseline characteristics (age, gender, race,
ethnicity) between the cases and the controls [Gruber et al. 1986]. In such cases, any
observed difference between the groups after a follow-up period might be due to the
difference in baseline characteristics and not due to the exposure. Therefore in such
cases, quantifying the real effect of exposure might be difficult.
Such bias can be overcome by finding the right control group. One possible way is
to randomly select subjects from a pool of patients such that the pool does not consist
of patients diagnosed with the outcome [Wacholder et al. 1992]. In other approaches,
controls can be drawn from neighborhood of the cases as such controls would be very
similar in terms of socio-economic status and lifestyle choices [Vernick et al. 1984].
Similarly, when genetic factors are the main focus of study, controls could often be
chosen from family and relatives as they share similar genetic make-up [Wacholder et
al. 1992].
Confounding is another issue which might undermine the internal validity of any
study [Abramson et al. 2001]. Confounding arises when a variable (i.e. confounder)
is associated with the exposure and influences the outcome, but the confounding
variable is not connecting the exposure with the outcome [Ory 1977]. For example,
studies have often reported a high degree of association between risk of myocardial
infarction and oral contraceptives. However, this association was later found to be
spurious because of the high proportion of tobacco users among users of birth control
pills. Therefore tobacco consumption confounded the relation between myocardial
infarction and oral contraceptives.
5. Metrics
Quantifying the outcome is the primary interest in many research studies. The
outcome is often quantified using various metrics such as incidence rate, prevalence,
relative risk and odds ratio [Hennekens et al. 1987]. Incidence rate [Last et al. 2001]
indicates the number of new cases of disease in a population at risk over a predefined
interval of time. Prevalence indicates the number of existing cases of disease in a
population under observation. For example, in a given population of 100,000 persons,
there were 980 patients who have the diagnosis of tuberculosis and there happen to be
10 patients freshly diagnosed with tuberculosis in the same year. In this scenario, the
incidence rate of tuberculosis within a year would be 10/99020 whereas the prevalence
rate would be 980/100000.
Relative risk is defined as the frequency of outcome in the exposed group as compared
to the frequency of outcome in the unexposed group. For example, consider a cohort
of pre-diabetic patients. The cohort is divided into two groups (control and treatment)
of 1000 patients each. The treatment group is prescribed statin and the control group
is not. The cohort is then followed for 5 years. After 5 years, it was observed that
200 patients in the treatment group progressed to diabetes whereas 100 patients in
the control group progressed to diabetes. From this information, the relative risk of
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Fig. 1: Study Design Classification Hierarchy
diabetes is 2.0: patients within treatment group are twice as likely to progress to
diabetes as controls. Relative risk is 1.0 when the frequency of outcome is same in
both the groups. Relative risk greater than 1.0 indicates increased risk of outcome in
the treatment group, while less than 1.0 indicates decreased risk (protective effect of
exposure).
Odds ratio can be defined as the odds of exposure/outcome among the intervention
group divided by the odds of the exposure/outcome among the non-inervention group.
For the example above, the odds in the case group will be 0.20 whereas the odds in the
control would be 0.10. The odds ratio would then be 2.0. In the following section, we
describe various study designs and metrics which are widely used in respective study
designs.
6. Study Design
EHR data is a mere collection of database tables that need to be transformed into an
analysis matrix that is amenable to data mining in a manner that allows us to answer
the question we set out to study. Suppose we wish to construct a risk prediction model
that can predict the 5-year risk of a particular disease D for any patient. To construct
such a model, we would take a cross section of the patient population in year Y , allow-
ing us to have a representative sample from which this “any patient” may come from.
Y is ideally at least 5 years before the last date in the EHR, so that we have sufficient
(5-year) follow-up for many patients. Next, we reconstruct all patients’ state of health
in year Y , collecting their medical history before Y ; and then follow them five years for-
ward (until year Y + 5) and establish their outcomes, namely whether they developed
D. The analysis matrix would have patients as its rows and patient characteristics in
year Y as columns; and would have an outcome for D, as well. Traditional predictive
modeling techniques are directly applicable to such a matrix for carrying out various
research related tasks.
The way we transformed that EHR data follows a particular study design that allows
us to answer our question. Each study question can require a different study design.
In this section, we review some of the most commonly used study designs and the
questions they allows us to answer. For additional details, the interested reader is
referred to [Grimes and Schulz 2002].
Study designs form a hierarchy which is depicted in Figure 1. Accordingly, at the
highest level, study designs can be primarily classified into two major groups i.e. ex-
perimental and observational.
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In an experimental study design, the researcher intervenes to change the course of
the disease and then observes the resultant outcome. Randomized Clinical Trials are
examples of experimental study designs. A specific example would be a study where
surgery patients with T2DM were randomized to receive supplemental insulin at bed-
time for blood glucose (treatment) or no supplemental insulin (control). As intervention
in EHRs is not possible, we will not discuss these study designs any further.
By observational [Funai et al. 2001], we refer to study designs where the re-
searchers do not intervene. In such studies, the treatment alloted to each subject is
beyond the control of the investigator. For example, consider a study that investigates
the effect of smoking (exposure) on lung capacity (outcome). A cohort of young men
aged 18-25 are identified. Some subjects in this cohort smoke tobacco (exposed group)
and some do not (unexposed/comparison group); the investigator has no influence on
which subjects smoke and which do not. This cohort is then followed for a number of
years to analyze the effect of smoking on lung capacity by comparing the exposed group
with the unexposed group [Kelsey 1996; Rothman and Greenland 1986]. Observational
studies can be further categorized as analytical (if there is a comparison group as in
the example given above) or descriptive (no comparison group).
Analytical studies are mostly used to test hypotheses about exposures and their
effects on the outcome. They can also be used to identify risk and protective factors for
diseases as well as causal associations between exposures and outcomes. Analytical
studies [Last et al. 2001] can be further divided into three major groups based on the
temporal direction in the study. Studies which start with an outcome and look back
in time for exposure are known as case-control studies. If the study begins with an
exposure and concludes with an outcome, we refer to them as cohort studies [Doll et
al. 2000; Hannaford and Kay 1998; Kim et al. 2000; Huang et al. 1999]. If we only
consider a single point in time, where the outcome and the exposure may both be
present at the same time, we refer to the study as cross-sectional [Last et al. 2001].
Descriptive study designs, which have no outcome of interest, mostly deal with
the frequency and the distribution of risk factors in populations and enable us to as-
sess the extent of a disease of interest. These study designs are usually used to build
hypotheses, thereby building the framework for future clinical research.
In Figure 1, we categorized studies as analytical or descriptive first and then cate-
gorized them further based on temporal direction. Alternatively, and equally correctly,
we could have categorized them based on temporal direction first. Studies that start
with a cohort selection and follow the cohort forward in time are called prospective;
studies that start with the outcome and look backwards in time are retrospective;
and studies that take a snapshot of the patient population at a particular point in
time are cross-sectional. Within each of these categories, we could further divide
them as analytical or descriptive. For example, a case-control study is a retrospective
analytical study; retrospective descriptive studies are also possible.
In the following section, we will discuss the aforementioned study-designs along
with clinically relevant examples. We will also discuss how certain study designs may
introduce biases and confounding factors.
6.1. Cohort Studies
Cohort studies are also known as incidence, follow-up, forward-looking, longitudinal,
prospective or concurrent studies [Lilienfeld and Stolley 1994]. The defining feature of
these studies is that we follow a cohort of patients over time. The cohort consists of
two kinds of patients: those who are exposed to a particular factor of interest (called
the exposed group) and those who are not exposed (unexposed or control group) at a
particular point in time (baseline). We follow this cohort and compare the incidence
of an outcome between exposed group with the unexposed group [Beral et al. 1999;
Seman et al. 1999; Colditz et al. 1996]. Often the exposure of interest is a treatment:
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the researchers are interested in assessing the effect of a treatment on an outcome. In
this case, the exposed group can also be called the treatment group.
As an illustration, let us consider the example of studying the effect of obesity on
diabetes. First, we decide on a baseline. Baseline can be a particular date (say Jan. 1st,
2005) or an event of interest such as patients reaching a particular age or developing
a particular condition. At baseline, we take a cross-section of our population. Some of
our patients already have diabetes, other do not; some of them are obese some of them
are not. Since our interest is the risk of developing diabetes, we exclude all patients
who are already diabetic; the remaining patients form our study cohort. Our exposure
of interest is obesity. The obese patients form the exposed group and the non-obese
patients the unexposed group. We then follow the cohort forward in time and observe
how many patients develop diabetes and how many remain non-diabetic among both
the exposed and the unexposed patients. We can then compute the odds (or hazard
ratio) of developing diabetes among those who are obese versus those who are not.
Cohort studies are considered to be the best study designs for ascertaining the in-
cidence, natural progression of a disorder as the temporal relationship between the
exposure and the outcome [Walline et al. 2001]. They are also useful in analyzing mul-
tiple outcomes that might arise after a single exposure. For example, smoking (i.e.
exposure) might lead to multiple outcomes such as stroke, oral cancer and heart dis-
ease.
However, such study designs come with certain caveats. Firstly, selection bias is in-
herent in such cohort studies [Sackett 1979]. For example, in a cohort study analyzing
effects of smoking on T2DM, those who smoke would differ in other important ways
(lifestyle) from those who do not smoke. In order to validate the effect of exposure (i.e.
smoking), both the cases and controls must be similar in all respects except for the
absence/presence of exposure and the outcomes. Secondly, loss of subjects due to cen-
soring might be a possibility, not only when the study is short, but particularly with
longitudinal studies that continue for decades. For example, progression from T2DM
to associated complications such as Peripheral Vascular Disease (PVD) and Ischemic
Heart Disease (IHD) takes around 5 to 10 years, and subjects may drop out over this
long period.
6.2. Case-Control Studies
Case-Control studies are study designs which look backward: i.e., the study cohort is
defined at a particular time (e.g. first heart attack) and the study looks backwards in
time to analyze the patients’ exposure(s). In such studies two groups are compared, one
consisting of patients with the outcome in questions (cases) and another one consisting
of patients without the outcome (controls). Case-control study design can be used to
identify risk factors that may contribute to an outcome by looking backwards in time
and comparing the exposure histories of patients across the case and control groups:
exposure that are more prominent in the case group can be risk factors and exposures
more prominent in the control group can be protective factors–when the subjects are
similar except for the exposure [Torrey et al. 2000; Xu et al. 2011b; Osaki and Minowa
2001; Avidan et al. 2001].
Let us return to our example (as illustrated in Section 6.1) of estimating the effect
of obesity on incident (newly developed) diabetes. We would select a group of patients
(cases) newly diagnosed with diabetes and matched them with another group of non-
diabetic patients (controls). Matching is performed on important characteristics in an
attempt to reduce the differences between the groups to the exposure alone. We would
track these patients backwards in time for a fixed number of years to determine their
exposure history (whether they were obese or not). We can then compute the odds of
developing diabetes in obese patients.
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Since we start with known outcomes, these study designs are very useful in the
investigating (i) slow-onset diseases such as cancer and T2DM where it takes a long
time for the disease to develop; and (ii) rare outcomes. In both cases, finding cases–
patients who have the outcome (disease) in question–would be difficult prospectively,
either because the study would require a long follow-up time or a very large initial
sample size. In case-control studies, cases and controls are identified at the beginning
of the study and are followed retrospectively.
Conversely, case-control study designs are inefficient when the exposure rate is low,
as researchers would have to analyze the entire data cohort to identify one patient
who had the exposure. For example using a case-control study design to investigate
the effect of pancreatic cancer (exposure) on T2DM (outcome) would be impractical
because the pancreatic cancer is very rare. In such cases, the cohort study design is
more effective.
Case-control designs are susceptible to biases. Recall bias can be introduced, where
the exposure may occur at a time when the patient is not under study, and thus an
exposure may remain undetected. Specifically, in case-control studies, selection of the
control group can also bias the results of the study and therefore researchers should
provide clear eligibility criteria for the outcome being studied, such as age, gender,
racial makeup or ethnicity.
In risk prediction, case control study designs are widely used due to their efficiency
in detecting the association between risk factors (exposure) and outcome.
6.3. Cross-Section Studies
Cross-sectional studies seek a comparison between cases and controls by collecting
data at one specific point in time [Lee 1994]. Such study designs differ from case-
control and cohort studies in that they aim to make inferences based on data that is
collected only once rather than collected at multiple time points [Mann 2003].
Returning to our example of measuring the effect of obesity on diabetes, we would
take a cross-section at a well-defined point in time (e.g. Jan 1, 2007). At this time, some
patients are diabetic, other are not; and some patients are obese and other are not. We
can compute the odds of having (not developing!) diabetes among obese patients versus
those who are not obese.
Note that this study design does not require the exposure to precede the outcome,
thus cannot discover causal relationships. For example, some of the obese patients may
have already been diabetic when they became obese.
The key advantage of the cross-sectional study design is that it only requires data
at a single point in time. In risk prediction, cross-sectional study designs are widely
used due to their ability to detect the association between risk factors (exposure) and
outcome using data at a single point in time. Strictly speaking, for risk prediction,
association is sufficient; the key drawback of this study design is that it cannot discover
causal relationships is neutralized.
6.4. Descriptive Studies
Descriptive studies are usually designed to analyze the distribution of variables,
without regard to an outcome [Walline et al. 2001; Hennekens et al. 1987]. The defin-
ing characteristic is that there are no cases or controls[Gabert and Stueland 1993;
Krane et al. 1988; Jaremin et al. 1996; Marshall et al. 1997; Giordano et al. 2002;
Weiss et al. 2005; Anderson et al. 1991].
At an individual level, descriptive studies include studies reporting an unusual dis-
ease or association and at a population level, they are often used for analyzing the
medical state of population for health-care planning [Tough et al. 2000; Bider et al.
1999; Dunn and Macfarlane 1996; Steegers-Theunissen et al. 1998]. For example, de-
scriptive designs are widely used to investigate tobacco usage within a population, age
group, gender or socio-economic class.
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One type of descriptive studies are correlational studies which aim to identify
associations between conditions: they typically investigate how predictive is a condi-
tion of another condition. With no information about the temporal ordering of these
conditions, we would not consider them as exposure of outcomes. One common use
of correlation analysis is to study the relationship between an index disease and its
comorbidities; or the relationships among diseases in multimorbid disease clusters.
In this case, the study is referred to as comorbidity analysis. For example, consider
our cohort of prediabetic patients, many of whom have different conditions (e.g. high
cholesterol, obesity, high blood pressure) at baseline. Using such study designs, we
can estimate the prevalence of these comorbid conditions. Further such analysis can
lead to future estimation of sequential patterns in which such diseases occur.
7. Approaches
Having defined some metrics of interest in Section 5, and having selected a study
design from Section 6 to transform our EHR data into an analytics matrix that data
mining methods can operate on, we appear ready to answer the clinical questions we
set out to solve. While the data format may suggest that we can directly apply our
existing data mining techniques, the data itself creates some challenges, which we
described in Section 4 in detail.
In this section, we describe approaches to address the challenges related to cen-
soring, the irregular temporal nature of the data and confounding. Approaches are
concepts and ideas that provide high-level solutions to these challenges; they are not
algorithms per se. Within these high-level solutions, concrete data mining techniques
can be developed. Our focus in this section is to describe these high-level ideas and
later, partly in this section as illustrative examples, but mostly in the subsequent sec-
tions, we will discuss some concrete analytics techniques that use these approaches.
Several survey articles and books have been published on the approaches we discuss
in this section. Chung et al. [Chung et al. 1991] provided a survey of statistical meth-
ods, which analyzes the duration of time until an event of interest occurs. Such modes
have been widely used to analyze the survival times of various events (e.g. mortality),
analyze the time until recidivism and many other applications. In their paper, they
summarized the statistical literature on survival analysis. A textbook by Klein and
Moeschberger [Klein and Moeschberger 2005] provides a comprehensive overview of
various techniques used to handle survival and censored data. Dahejia et al. [Dehejia
and Wahba 2002] discussed causal inference and sample selection bias in non exper-
imental settings. In their paper, they discussed the use of propensity score-matching
methods for non-causal studies and discussed several methods by implementing them
using data from the National Supported Work experiment.
7.1. Handling Censored Data
As discussed in Section 4.1 Censoring occurs when a patient’s trajectory is only par-
tially observable. For example, suppose a study is conducted to measure the impact of
a diabetes related drug on mortality rate. In such a study, let us assume that the indi-
vidual withdrew from the study after following the study course for limited duration.
In such a scenario, information about patient’s vital statistics is only available until
the patient was censored. Such data is common in domains such as healthcare and
actuarial science.
Survival analysis is an area of statistics that deals with censored data. These ap-
proaches usually aim to answer questions such as the following: what proportion of
the population will survive past a time of observation and what characteristics in-
fluence the probability of survival? To answer, the aforementioned clinical questions,
techniques are required which can handle censoring, which is frequently present in
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EHRs. Techniques to handle censored data, can be divided into three major categories:
non-parametric, semi-parametric or parametric.
Non-parametric techniques do not rely on assumptions about the shape or parame-
ters of the distribution of time to event. Examples of such techniques include Kaplan-
Meier estimators [Kaplan and Meier 1958] and Nelson- Aalen estimators [Cox 1992].
Rihal et al. [Rihal et al. 2002] used Kaplan-Meir estimators for incidence and prognos-
tic implications of acute renal failure in patients undergoing percutaneous coronary
intervention (PCI). Dormandy et al. [Dormandy et al. 2005] used Kaplan-Meier esti-
mates in their analysis of patients who were diagnosed with T2DM and were at high
risk of data and non-fatal myocardial infarction and stroke. Rossing et al. [Rossing et
al. 1996] used Nelson-Aalen estimators for analyzing the predictors of mortality in in-
sulin dependent diabetes. Ekinci et al. [Ekinci et al. 2011] used such non-parametric
techniques for exploring salt intake consumption and mortality in patients with diag-
nosed with T2DM.
Parametric techniques often rely on theoritical assumptions about the shape or pa-
rameters of the distribution of time to event. Examples of such technique are the accel-
erated failure time models (AFT models) [Keiding et al. 1997] which are an alternative
to the widely used proportional hazard models. Babuin et al. [Babuin et al. 2008] deter-
mined whether troponin elevations influence short and long term mortality in medical
intensive care unit patients. Wilson et al. used [Wilson et al. 2008] used AFT models
to predict cardiovascular risk by using predictors such as age, gender, high-density
lipoprotein cholesterol, diabetes mellitus (DM), cholesterol, smoking status, systolic
blood pressure and body mass index (BMI).
Semi-parametric techniques have both parametric and nonparametric components.
An example of such a technique is the proportional hazards model. Proportional haz-
ards models relate one or more covariates with the time that passes before some event
occurs. Yadav et al. [Yadav et al. 2015b] used the proportional hazards model for risk
assessment of comorbid conditions in T2DM. They identified how risks vary across
sub-populations for the same outcome. The sub-populations were defined by using di-
agnosis codes such as hypertension, hyperlipidemia and T2DM with time to death
being modeled as the outcome of interest. Martingale residuals were used to compute
the risks. Vinzamury and Reddy [Vinzamuri et al. 2014] extended proportional haz-
ards regression and proposed sophisticated techniques which can capture grouping
and correlation of features effectively. They proposed novel regularization frameworks
to handle correlation and sparsity present in EHR data. Further, they demonstrated
the applicability of their technique by identifying clinically relevant variables related
to heart failure readmission.
7.2. Handling Irregular Time Series Data
Data stored in EHRs is usually collected through longitudinal study. In such stud-
ies, the subject outcomes, treatments or exposures are collected at multiple follow-
up times, usually at irregular intervals. For example, patients diagnosed with T2DM
might be followed over time and annual measures such as Hemoglobin A1c and GFR
are collected to characterize the disease burden and health status, respectively. As
these repeated measures are correlated within the subject, they require sophisticated
analysis techniques. In what follows, we describe techniques that are widely used to
handle these repeated measurements. In particular, we cover marginal and condi-
tional models, respectively. These models handle unevenly spaced (irregular) EHRs
by assuming a correlation structure among multiple clinical observations of a patient
recorded at different time points.
Marginal models are also known as the population averaged model as they make
inferences about population averages. In such models, the target of inference is usu-
ally the population and these models are used to describe the effect of covariates on
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the average response. They are also used to contrast the means in sub-populations
that share common covariate values. For example, consider a cohort of pre-diabetic
patients with elevated cholesterol levels. In this cohort, if we are interested in esti-
mating the progression of patients to full-blown T2DM, we would probably want to
use the population-averaged coefficients. Generalized Estimating equations (GEE’s)
are mostly used for parameter estimation in marginal models. This approach is com-
putationally straightforward and with care can handle missing data, even when the
covariance has been misspecified. Such modeling techniques are widely used in epi-
demiological studies, particularly in multi-site cohort studies as they incorporate the
effect of unmeasured dependence across outcomes.
Conditional models [Laird and Ware 1982] are also known as the locally averaged
models as they usually make inferences about individual subjects. The estimates are
based on averaging or smoothing done by the model, but more locally, are based on
sources of dependence in estimating model parameters. For example, consider once
again our aforementioned cohort of pre-diabetic patients with elevated cholesterol lev-
els. In this cohort, if we are interested in estimating the effect of statin across every in-
dividual, we would use conditional models. Yamaoka et al. [Yamaoka and Tango 2005]
used conditional models to evaluate the effect of lifestyle change recommendations for
preventing T2DM in individuals at high risk. They observed that lifestyle education
intervention reduced glucose levels by 0.84 mmol/l in the case group as compared to
the control group.
7.3. Handling Confounding
A confounding variable can be defined as an extraneous variable that correlates
with both the dependent and the independent variable. To handle confounding we
discuss techniques such as propensity scoring and inverse probability weighing.
Statistical matching techniques such as propensity score matching (PSM) [Peikes et
al. 2008] aim to estimate the effect of an intervention by incorporating the effect of
covariates that predict receiving the intervention. They aim to reduce the bias caused
by confounding variables. PSM creates a group by employing the predicted probability
of group membership which is usually obtained from logistic regression. The key
advantage of PSM is that by using a linear combination of features, it balances both
the intervention and the non-intervention group on a large number of covariates. One
disadvantage of PSM is that it only accounts for known covariates i.e. variables which
are observed. Another issue is that PSM requires large samples, with substantial
similarities in terms of subjects between treatment and control groups. Polkinghorne
et al. [Polkinghorne et al. 2004] used PSM to analyze the inception and intervention
rate of native arteriovenous fistula (AVF).
Inverse probability weighting [Hogan and Lancaster 2004] is a statistical technique
for calculating statistics which aim to standardized to a population as compared to the
population from which the data was collected. Instead of adjusting for the propensity
score, the subjects are usually weighted. However, factors such as cost, time or
ethical concerns might prohibit researchers from directly sampling from the target
population. Robinson et al [Robinson et al. 2011] used inverse probability weighting
for examining whether lower serum levels of serum 25-hydroxyvitamin are associated
with increased risk of developing type 2 diabetes.
8. Clinical Data Mining Methodologies
The discipline of EHR data mining stands at the intersection of epidemiology, bio-
statistics and general data mining. From epidemiology and biostatistics, clinical data
mining has borrowed study design, the methodology that allows us to organize EHR
data into a matrix that is amenable to the application of data mining algorithms
that can correctly answer meaningful clinical questions. It has also borrowed basic
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Unsupervised Supervised
Time Agnostic Atemporal Descriptive Studies
(8.1.1)
Cross-Sectional Studies (8.2),
Cohort and Case-Control Stud-
ies (8.3.1)
Time Aware Temporal Descriptive Studies
(8.1.2)
Cohort and Case-Control Stud-
ies (8.3.2)
Table I: Structure for Section 8
approaches from biostatistics and epidemiology to address the challenges that EHR
data poses, including censoring, analysis of irregular time series data and methodolo-
gies for causal inference1. In this section, we focus on the contributions of general data
mining.
Traditionally, data mining techniques [Tan et al. 2006] are broadly categorized as
supervised or unsupervised: supervised methods take an outcome into account, while
unsupervised methods simply learn from the structure of the data. This distinction
neatly maps to study designs: supervised techniques are applicable to analytical stud-
ies and unsupervised techniques to descriptive studies.
The hallmark of EHR data is its temporal nature, suggesting that data mining tech-
niques be further categorized based on their ability to take time into account. We call
a data mining algorithm and its resulting model time-aware, if outcome of interest de-
pends on time; and we call it time-agnostic, if it builds a model that does not take time
into account.
Although EHR data is inherently temporal, time is not always of relevance. The
clinical question we aim to answer may be temporal if time is of relevance (i.e. time is
part of the question) or it may be atemporal (not temporal) if time is not part of the
question. Atemporal questions are naturally answered by time-agnostic data mining
techniques. On the other hand, temporal questions can be either answered by time-
aware models or if the question can be transformed into a simpler atemporal question,
they can also be solved using time-agnostic models. For example, predicting the risk of
30-day mortality after surgery is a temporal question (time is part of the question) but
it can be solved using time-aware models (e.g. Cox model) or time-agnostic models (e.g.
logistic regression).
The study design dictates whether a question can be temporal or atemporal and it
also determines in large part whether any of the challenges posed by EHR data can
be successfully addressed. For this reason, we describe data mining techniques that
are commonly applied in the context of the applicable study designs. In Table 1, we
present the structure of the following subsections.
8.1. Descriptive Studies
Descriptive studies represent the broadest variety of inquires we can undertake,
ranging from simple statistics (prevalence rate, incidence rate) to descriptions of the
progression of a particular diseases via case studies. Such simple applications do not
require data mining, but data mining techniques enable more advanced applications
including comorbidity analysis and trajectory mining. While descriptive studies cover a
wide range of applications, their defining characteristic is that no comparison is made
between patients (or patient groups) with and without a particular outcome. Without
a particular outcome, we cannot have outcome labels and hence the problem at hand
is unsupervised.
1The roots of causal inference are in computer science,but has been embraced by epidemiology and biostatis-
tics resulting in the development of the advanced techniques we described earlier.
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Descriptive studies are commonly used to answer both temporal and atemporal clin-
ical questions. For example, estimating prevalence rates at a particular time is an
atemporal clinical question, while extracting the trajectory of a patient as sequences
of diagnosis codes is naturally a temporal clinical question. Therefore both time-aware
and time-agnostic data mining techniques are applicable for descriptive studies.
8.1.1. Atemporal Descriptive Studies:Atemporal descriptive studies can arguably be han-
dled using standard textbook methods. A prototypical application of this nature would
be to take a snapshot of the population at a particular time and cluster the patients
based on the conditions they present. One option is to “flatten” the temporal dimen-
sion of the data through temporal abstraction, e.g. by extracting features and applying
non-temporal unsupervised techniques.
In this section, we discuss how unsupervised techniques have been widely used for
identifying clusters of patients that have similar characteristics (e.g. demographics,
medications, diagnosis codes, laboratory test results) and for finding associations be-
tween clinical concepts (e.g. medications, diagnosis codes and demographic attributes).
Next, we describe how these techniques make use of the approaches we discussed in
Section 7.
Clustering: Gotz et al. [Gotz et al. 2011a] used clustering techniques for identifying
a cohort of patients similar to a patient under observation. They used the cohort
as a surrogate for near-term physiological assessment of the target patient. Roque
et al. [Roque et al. 2011] stratified patients using hierarchical clustering, where
the distance between patient records was computed using the cosine similarity of
diagnosis codes. Along similar lines, Doshi et al. [Doshi-Velez et al. 2014] investigated
the patterns of co-occurring diseases for patients diagnosed with autism spectrum
disorders (ASD). They identified multiple ASD related patterns using hierarchical
clustering. They further discussed how the aforementioned patterns can be attributed
to genetic and environmental factors. Kalankesh et al. [Kalankesh et al. 2013] noted
that representing the medical state of a patient with diagnosis codes can lead to sparse
clusters since EHRs contains a large number of diagnosis codes often running into
thousands. To overcome this problem, they used Principal Component Analysis (PCA)
[Dunteman 1989] to reduce the dimensionality, thereby making the structure more
amenable for visualization and clustering. Marlin et al. [Marlin et al. 2012] developed
a probabilistic clustering method along with temporal abstraction to mitigate the
effects of unevenly spaced data, which is inherent in EHRs.
Association Analysis: Association rule mining techniques [Agrawal et al. 1994]
such as Apriori have also been used on EHR data to identify associations among
clinical concepts (medications, laboratory results and problem diagnoses). These tech-
niques have the ability to discover associations and interpretable patterns from EHRs
data. However, the performance of such techniques often deteriorates when there
are a large number of clinical variables present in EHRs. Wright et al. [Wright et al.
2010] used the Apriori framework to detect transitive associations between laboratory
test results and diagnosis codes and between laboratory test results and medications.
For example, they observed some unexpected associations between hypertension and
insulin. They attributed this finding to co-occurring diseases and proposed a novel way
to identify such transitive associations. Cao et al. [Cao et al. 2005] used co-occurrence
statistics to identify direct and indirect associations among medical concepts. Holmes
et al. [Holmes et al. 2011] used statistical approaches to detect associations between
rare diseases. They observed that analyzing cohorts comprised of sick patients leads
to identification of significant findings. Shin et al. [Shin et al. 2010] used association
rule mining to identify co-morbidities (e.g. non-insulin dependent diabetes mellitus
(NIDDM) and cerebral infarction) which are strongly associated with hypertension.
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Hanauer et al. [Hanauer et al. 2009] used statistical tests to observe common path-
ways for diseases such as granuloma annulare and osteoarthritis.
Challenges and Limitations: In Section 4, we identified a number of challenges,
centered around three key challenges: censoring, irregular time series, and causation.
In this paragraph, we describe the limitations of these methods in relation to these
challenges.
While individual techniques all have their own limitations, methods that are ap-
plied specifically to atemporal descriptive studies share some limitations stemming
from the nature of the study design. Atemporal descriptive studies, as all atemporal
studies, deal with information collected at one time instant (at baseline) or summa-
rized until baseline. With only one time point, this study design completely sidesteps
the challenges stemming from irregular time series—naturally at the cost of losing in-
formation: a potentially long sequence of information has been aggregated to a single
time point.
Atemporal studies (and the data mining methods that are applicable to these stud-
ies) are susceptible to biases stemming from censoring. Right censoring is obviously
present as we cannot observe any change in the patients’ condition after baseline.
Suppose we have two patients, neither of whom has a condition at baseline, but one
develops it shortly after baseline, while the other develops only decades later (or not
at all). These patients are clearly different for the purpose of the analysis, but the
atemporal methodologies consider them identical, which consitutes information loss.
A similar situation arises with left censoring: we may not know how long a patient
has had a condition for but if we had that information, we could obtain more accurate
results.
Causation is generally not possible under atemporal descriptive studies. First, de-
scriptive studies do not differentiate between exposures and outcomes; thus trying to
establish causation is meaningless. Second, even if we attempted to establish causa-
tion between two conditions, due to the atemporal nature of the study, we cannot even
ascertain that one happens before the other.
While these methods are rather limited, their popularity stems from their simplicity.
Most off-the-self data mining algorithms are directly applicable.
8.1.2. Temporal Descriptive Studies:Time plays an important role in the clinical ques-
tions. For example, the sequence of events, timing between events, etc. Standard
textbook data mining techniques exist to solve such problems (e.g. sequence mining,
Markov models), but to achieve better results, significant improvements have been
proposed. We broadly classify the approaches that can be carried out using such tech-
niques as those which use time-aware techniques, e.g., sequence mining, time-lagged
correlations, etc., and those which simplify the problem and apply time-agnosic tech-
niques e.g., temporal-abstraction (summarizing the longitudinal data) and Hidden
Markov Models (HMM) trajectory clustering (using HMM to simplify away time so
that standard clustering is applicable).
Temporal Abstraction Framework: The temporal abstraction framework has been
frequently used to prepare patterns from EHR data. Patterns can be abstracted us-
ing state representations (e.g. high, medium or low) or trend representations (e.g. in-
creasing, decreasing, constant). Shahar et al. [Shahar 1997] provided a mechanism to
abstract patterns from unevenly spaced time-series. Such time-series are common in
EHR data elements such as laboratories test results and vitals. They further proposed
temporal logic relations to combine patterns generated from univariate time-series.
Sacchi et al. [Sacchi et al. 2007] extended the temporal abstraction framework to gen-
erate temporal association rules (TARs). In TAR’s, the antecedent and the consequent
both consist of temporal patterns generated using the temporal abstraction frame-
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work. Jin et al. [Jin et al. 2008] further extended the TAR framework, to generate
rules for mining surprising patterns. In such patterns, certain events lead to unex-
pected outcomes, e.g. taking multiple medicines together sometimes causes an adverse
reaction. Batal et al. [Batal et al. 2009] used the temporal abstraction framework to
propose the Segmented Time Series Feature mining algorithm for identifying the fre-
quent patterns from an unevenly sampled time-series. Such modeling techniques have
their own set of challenges. Patterns generated from individual patient time series are
susceptible to noise. Further, such patterns can be of uneven temporal duration.
Trajectory Clustering: Clustering techniques have also been used to group EHR
data. Ghassempour et al. [Ghassempour et al. 2014] used HMM to cluster patient
medical trajectories. In their approach, they used both categorical variables (diagno-
sis codes) and continuous variables (vitals and laboratories test results) for clustering.
They first mapped each medical trajectory to an HMM and then used KL divergence
to compute the distance between two HMM’s.
Sequential Rule Mining: Researchers have explored sequential association rule
mining techniques for identifying causal relationships between diagnosis codes.
Hanauer and Ramakrishnan [Hanauer and Ramakrishnan 2013] identified pairs of
ICD-9 codes which are highly associated. They observed interesting temporal relation-
ships between hypothyroidism and shingles (herpes reactivation). Liao and Chen [Liao
and Chen 2013] proposed a sequential pattern mining approach to mine sequences
with gap constraints. Such gaps represent the delay between two concepts. Hripsack
et al. [Hripcsak 2013] measured lagged linear correlation between EHR variables and
healthcare process events. In their analysis, they considered five common healthcare
process events: inpatient admission, outpatient visit, inpatient discharge, ambulatory
surgery and emergency department visit and computed their correlation with several
EHR variables such as laboratory values and concepts extracted from clinical notes.
Visualization: Research has also been carried out in analytical reasoning facilitated
by advanced interactive visual interfaces. Research has been carried out by highlight-
ing the opportunities and associated challenges [Caban and Gotz 2015], cohort anal-
ysis and exploration [Zhang et al. 2014b; Gotz et al. 2012a], exploring comorbidities
[Gotz et al. 2012b; Sun et al. 2010], exploring concepts [Cao et al. 2011b], clinical
decision support [Gotz et al. 2011b], cohort identification [Cao et al. 2011a], disease
network visualization [Perer and Sun 2012] and temporal frequent event sequences
[Perer and Wang 2014].
Challenges and Limitations: Method applied in the context of temporal descrip-
tive studies have access to granular temporal information, and thus, in theory, they
can utilize more information than the atemporal descriptive methods from Section
8.1.1. Even when the methods themselves are unable to utilize the granular temporal
information, the study design allows them to produce results that are qualitatively
different. Atemporal descriptive studies are limited to using prevalence (proportion
of patients in a population presenting with a condition), while temporal descriptive
studies can use incidence (proportion of patients developing disease within a relatively
short time frame) as well as prevalence.
Naturally, these techniques can overcome the challenges of irregular time series ei-
ther directly (e.g. time lagged correlation) or through transforming a temporal problem
to an atemporal one by temporal abstraction or by enumerating the sequences of the
events.
Another challenge that temporal studies can overcome is handling censored data.
The information loss in conjunction with censoring that we described in the previous
section can be reduced. In case of atemporal descriptive studies, we have absolutely
no information regarding when patients develop each condition of interest; the only
information we have is binary indicating whether they have it at baseline. In contrast,
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in case of temporal descriptive studies, even in the presence of left censoring we know
that a patient has had the condition for at least a certain amount of information and
conversely, in case of right censoring, we know that the patient remains free of that
condition for at least a certain amount of time. While the techniques we described in
this section, did not make use of this information, it is possible to develop techniques
based on survival analysis that can.
Similarly to atemporal descriptive studies, causation remains impractical for tempo-
ral descriptive studies. In case of causation, we are generally interested in the causal
effect of an exposure on an outcome. These methods are still operating under the
framework of descriptive studies, thus they do not distinguish between exposure and
outcome.
8.2. Cross-Sectional Design
Cross-sectional studies are carried out by collecting data at one time point. The aim
of such studies is usually to identify and analyze the correlations between risk fac-
tors and the outcome of interest. In such studies, data is often collected on individual
characteristics, such as exposure to risk factors, demographic attributes and informa-
tion about the outcome. In what follows, we will describe the techniques often used
for such study designs along with examples of research carried out using data mining
algorithms.
When a study is designed as cross-sectional, supervised time agnostic data mining
techniques are the natural modeling choices. When the study is inherently temporal
and employs a cross-sectional design it can still be solved using supervised time agnos-
tic techniques, but we incur some loss of information due to temporal abstraction. For
example, a study investigating the 30-day mortality of patients following an exposure
can be modeled using supervised, non-temporal techniques as long as we only consider
a binary outcome, namely, whether the patients survived for 30 days or not. Since in-
terest in a specific outcome is very natural and there is great appeal in simplifying
these problems to become solvable through relatively simple supervised non-temporal
data mining techniques, such techniques have been applied to a broad spectrum of
problems, including risk prediction for hospitalization, re-hospitalization, diagnostic
and prognostic reasoning.
Rule Based Methodologies: White et al. [White et al. 2013] conducted a large scale
study for analyzing web search logs for detection of adverse events related to the drug
pair, paroxetine and pravastatin. They analyzed whether the drug interaction leads
to hyperglycemia. Iyer et al. [Iyer et al. 2014] used NLP techniques for mining clini-
cal notes to identify events related to adverse drug-drug associations. Haerian et al.
[Haerian et al. 2012] hypothesized that adverse events might be caused by the pa-
tient’s underlying medical condition. Along similar lines, Vilar et al. [Vilar et al. 2012]
used disproportionality based techniques to analyze adverse drug events related to
pancreatitis, Li et al.[Li et al. 2014] used penalized logistic regression to analyze asso-
ciations between ADRs and Epstein et al. [Epstein et al. 2013] used NLP techniques to
analyze medication and food allergies. Supervised non-temporal methodologies have
been frequently used in the form of rule-based techniques for cohort identification.
Phenotyping algorithms for diseases such as celiac disease, neuropsychiatric disor-
ders, drug-induced liver injury and T2DM [Pathak et al. 2013; Carroll et al. 2011;
Xu et al. 2011a] have been widely explored. Supervised pattern mining approaches
using the temporal abstraction framework have been used for predicting Heparin In-
duced Thrombocytopenia (HIT) [Batal et al. 2009]. Batal and Hauskrecht [Batal and
Hauskrecht 2010] used such methodologies to generate minimal predictive rules for
Heparin Platelet Factor 4 antibody (HPF4) test orders. They further extended their
approach by introducing the minimal predictive patterns (MPP) framework wherein
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they directly mine a set of highly discriminative patterns [Batal et al. 2012]. Those
patterns were later used for classification of related tasks.
Bayesian Networks: Bayesian Networks have also been used to model EHRs for di-
agnostic reasoning (constructing the medical state of the patient using laboratory test
results), prognostic reasoning (prediction about the future) and discovering functional
static interactions between the outcome and the predictors [Lucas et al. 2004]. Zhao
et al. [Zhao et al. 2011] integrated EHR data with knowledge from other sources such
as Pubmed to develop a weighted Bayesian network for pancreatic cancer prediction.
They also discussed how their approach can be used to detect clinically irrelevant vari-
ables for disease prediction. Sverchkov et al. [Sverchkov et al. 2012] compared clinical
datasets by capturing the clinical relationships between the individual datasets by us-
ing the Bayesian networks. The multivariate probability distributions were then used
to compare the clinical datasets.
Challenges and Limitations: Methods under cross-sectional design are similar
to methods under descriptive atemporal design in that they are all atemporal: they
only consider a cross-section taken at one point in time. Therefore, the limitations
associated with atemporal design, namely the lack of ability to handle censoring and
to make use of the granular time information in the EHR apply to cross-sectional
designs, as well.
The key difference between a cross-sectional and descriptive study design lies in the
existence of comparison groups and thus a distinction between exposure and outcome.
Although this difference allows for qualitatively different results–we can now measure
risks–it still is not practical for causal inference because we cannot establish the tem-
poral relationship between exposure and outcome. To establish causation, we need to
ascertain that the exposure precedes the outcome.
8.3. Cohort and Case-Control Study Design
Cohort and Case-Control studies compare patient groups with different exposures
over time and record their outcomes. They differ in the direction in which time is ob-
served: in cohort studies patients are followed from exposure to outcome and in Case-
Control studies, patients are followed from outcome to exposures. While this difference
has far-reaching consequences on the required sample sizes, exposure rates and the
metrics we can estimate, once the design matrix has been constructed, the same data
mining methods apply to both of these study designs. Hence, we consider these two
designs together.
What is common across these study designs is that they are best suited to answer
temporal questions. As it is typical with temporal questions, we can use either time-
aware models or we can simplify the question such that it can be answered using
time-agnostic models. In the following paragraphs, we provide examples of both.
8.3.1. Time-Agnostic Models for Cohort and Case-Control Studies:Time Agnostic Regres-
sion: Supervised time-agnostic models are commonly employed when time-to-event
can be removed from the clinical question. For example, time-to-rehospitalization can
be simplified to the binary outcome of 30-day rehospitlaization (yes/no) of 30-day-
rehospitalization (yes/no) which does not include time. Applications of supervised time-
agnostic modeling include supervised feature creation [Aliferis et al. 2010], predicting
the onset of neonatal sepsis [Mani et al. 2014], potentially preventable events [Sarkar
and Srivastava 2013], 30 day hospital readmissions [Cholleti et al. 2012; Park and
Ghosh 2014], post-hospitalization VTE risk [Kawaler et al. 2012], T2DM risk fore-
casting [Mani et al. 2012], atrial fibrillation [Karnik et al. 2012], 5 year long life ex-
pectancy risk calculation [Mathias et al. 2013], risk of depression using diagnosis codes
[Huang et al. 2014], survival of heart-lung transplant patients [Oztekin et al. 2009],
breast cancer survivability [Sarvestani et al. 2010], 30 day mortality in patients suffer-
ing with cardio-vascular diseases, risk of retinopathy in patients suffering from type
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1 diabetes mellitus (T1DM) [Skevofilakas et al. 2010], mortality in patients suffering
from acute kidney injury [Matheny et al. 2010], mortality prediction in ICU [Hera-
sevich et al. 2013] and risk of dementia [Maroco et al. 2011]. For these analyses, al-
most all flavors of common predictive modeling techniques ( decision trees [Mani et
al. 2012; Sarvestani et al. 2010; Austin et al. 2012], ensemble techniques (e.g. bag-
ging,boosting,random forests) [Cholleti et al. 2012; Kawaler et al. 2012; Mani et al.
2014; Karnik et al. 2012],naive Bayes [Kawaler et al. 2012; Karnik et al. 2012; Sar-
vestani et al. 2010], linear regression, support vector machines [Mani et al. 2012] and
logistic regression [Zhai et al. 2014; Mani et al. 2012; Cholleti et al. 2012; Huang et
al. 2014; Chang et al. 2011] have been used. These techniques have also been used
for identification of regional differences in breast cancer survival rates despite guide-
lines [Ito et al. 2009], comparison of cancer survival rates across continents [Cole-
man et al. 2008], comparison of cancer and survival patients over time, exploring
relationships between hospital surgical volumes and 5 year relationship of stomach
cancers [Nomura et al. 2003], comparing dosage volumes of warfarin in European-
American and African-American [Ramirez et al. 2012], postpartum depression rates in
Asian-American subgroups (Indian, Vietnamese, Chinese, Korean, Filipino, Japanese,)
[Goyal et al. 2012], analyzing the effect of different ethnicities on different levels of
susceptibility to diabetes related complications and studying the detrimental effect of
fibrates on women as compared to men in a population presenting with high choles-
terol levels.
Ghalwash et al. [Ghalwash and Obradovic ] proposed predictive modeling technique
to find a suitable duration of the hemoadsorption (HA) therapy control and observed
that their method led to substantial monetary savings. Sun et al. [Sun et al. 2014]
worked on predicting the risk and timing of deterioration in hypertension control by
analyzing critical points in time, at which hypertension status is at borderline (clinical
limit separating control vs out-of-control)l. Wang et al. [Wang et al. 2015b] developed
a dynamic Poisson autoregressive model for flu forecasting where in they allowed the
autoregressive model to change over time. Panahiazar et al. [Panahiazar et al. 2015]
built a heart failure risk prediction model using several machine learning techniques
where in they included multiple comorbidities which lead to improvement in prognos-
tic predictive accuracy. Wang et al. [Wang et al. 2014a] proposed Multilinear sparse
logistic regression to handle data in the form of multi-dimensional arrays. They used
their methods to predict the onset risk of patients with Alzheimer’s risk and heart fail-
ure.
Overcoming Challenges: Such techniques also have their own share of caveats.
Causal analysis is not possible as time-to-event data is often ruled out and there is
no way to ascertain the relationship between diseases and the outcome of interest.
The inherent design of such techniques rules out longitudinal analysis. Temporal ab-
straction is also employed to summarize time. As comparison groups are available in
such study designs they are well-suited for applications such as risk prediction. Fur-
ther, handling right censored data is not possible but handling left censored data and
interval censored data is plausible.
Challenges and Limitations: Case-control and cohort study designs are the most
flexible and informative designs among the study designs we consider. These designs
have dedicated exposures and outcomes, allowing for measuring risks; and they have
detailed temporal information allowing to measure time to event and establish the
precedence (temporal ordering) of events. Unfortunately the time-agnostic methods
handicap the study design. Simplifying this study design to become atemporal, effec-
tively renders the study design into a cross-sectional design with some amount of ex-
tra information about outcome (did it happen within a certain time-frame). Since the
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design has been effectively reduced to cross-sectional, the limitations of cross-section
designs stand, but to a lesser degree.
In case of a cross-sectional design, we have no information about the timing of the
outcome. In contrast, in case of case-control studies, even when we use time-agnostic
methods, we usually have some information about the time of the outcome: e.g. the pa-
tient did not develop the disease in a certain time frame (say 5 years). The information
these methods discard concerns patient who did not develop the disease: patients who
got censored (are lost to follow-up within 5 years without developing the disease) are
ignored, even though these patients carry partial information to the effect that they
did not develop the disease for some amount of time (which is less than 5 years).
The key advantage of these methods over cross-sectional design lies in causation.
Although we do not have detailed time-to-event data, we know that the exposure pre-
cedes the outcome, and we also have a distinction between exposure and outcome, thus
causal inference is possible.
8.3.2. Time-Aware Models for Cohort and Case/Control Studies:Supervised time-aware
models are utilized when the clinical question cannot be simplified or if the simplifica-
tion to time-agnostic modeling comes at a significant loss of information. Such question
focuses on the time-to-event itself (clearly cannot be simplified), sequences of events or
when time-to-event carries additional information about the outcome. Continuing with
the example of 30-day rehospitalization, by simplifying the outcome to binary yes/no,
we lose information since we ignore whether the patient was re-hospitalized in (say) 7
days vs 20 days. The former case is clearly more severe.
Many of the temporal clinical questions are related to right censoring. Survival mod-
eling, which was specifically developed for this purpose, is the quintessential technique
for this study design. Survival modeling is a suite of techniques with various special-
izations that share a common characteristic of being able to handle time and censoring.
Other techniques which incorporate the effect of time include dynamic Bayesian net-
works, sequential pattern mining, etc.
Survival Modeling: Wells et al. [Wells et al. 2008] hypothesized that patients di-
agnosed with T2DM have an increased risk of mortality. They used Cox proportional
hazards regression with time to death as the outcome. They also observed that cer-
tain interaction terms involving medications and age were significant indicators. Vin-
zamury and Reddy [Vinzamuri and Reddy 2013] extended Cox proportional hazards
regression which aims to capture the grouping and correlation of features effectively.
They proposed novel regularization frameworks to handle the correlation and sparsity
present in EHR data. They demonstrated the applicability of their technique by iden-
tifying clinically relevant variables related to heart failure readmission. Vinzamury
et al. [Vinzamuri et al. 2014] proposed a novel active learning based survival model
wherein continuous feedback from a domain expert can be utilized to refine the model.
Survival modeling techniques on time-to-event data have been explored widely in the
past. Cox regression [Cox 1992; Vinzamuri and Reddy 2013] is one of the most com-
monly used survival regression models. Its formulation, namely its semi-parametric
nature,with the mild assumption of the proportionality of hazards, makes it ideal for
many practical applications in fields such as economics [Wooldridge 1992], healthcare
[Ikeda et al. 1991; Liang et al. 1990; Lumley et al. 2002] and recommendation systems
[Kapoor et al. 2014].
Cox models, as most other regression techniques, are susceptible to overfitting. Stan-
dard regularization techniques, developed for other regression methods, have been ap-
plied to Cox models, as well. Lasso [Tibshirani et al. 1997] and elastic-net regularized
Cox models [Simon et al. 2011b] have been developed, and have been further extended
by regularizing them with convex combinations of L1 and L2 penalties [Zhang and Lu
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2007]. We are not aware of regularization for time-dependent covariate Cox models
[Therneau and Crowson 2014], which would be a straightforward extension.
Reddy et al. [Vinzamuri et al. 2014] proposed a new survival modeling algorithm
which uses a sophisticated discriminative gradient based sampling scheme and ob-
served better sampling rates as compared to other sampling strategies. To handle
correlated and grouped features, they proposed correlation based regularizers with
Cox regression which are commonly seen in many practical problems [Vinzamuri and
Reddy 2013]. Kuang et al. [Zhang et al. 2013] proposed Net-Cox, a network based Cox
regression model to handle the high-dimensionality of high-throughput genomic data.
They further applied their model to a large-scale survival analysis across multiple
ovarian cancer datasets.
Support vector machines [Hearst et al. 1998] models have also been extended to
handle censored data [Khan and Zubek 2008; Evers and Messow 2008; Shivaswamy et
al. 2007; Van Bellev et al. 2007; Shiao and Cherkassky 2014]. In such techniques, often
the task is converted into a ranking problem via the concordance index. This in turn
is efficiently solved using convex optimization techniques. Along similar lines, Khosla
et al. [Khosla et al. 2010] proposed algorithms which combine margin-based classifiers
along with censored regression algorithms to achieve higher accuracies (concordance
in this case). They used their technique to identify potential novel risk markers for
cardiac problems.
Research has also been carried out on extending decision trees to handle censored
data [Gordon and Olshen 1985]. Ishwaran et al. [Ishwaran et al. 2008] proposed
Random Survival Forests for analyzing right censored survival data. They analyzed
splitting rules for growing survival trees, introduced a new measure of mortality
and applied it for patients diagnosed with coronary artery disease. Neural nets have
also been adapted to handle censored data with varying results [Kattan et al. 1998;
Snow et al. 1994]. Techniques such as reverse survival [Yadav et al. 2015a] have also
been explored in the past wherein they go further back in time.
Dynamic Bayes Networks: While survival models are by far the predominant
type of models, other methods that can incorporate temporal information also exist.
Dynamic Bayesian networks (DBN) [Melnyk et al. 2013] have been used to model
temporal relationships among EHR variables [Rana et al. 2015]. Nachimuthu et al.
[Nachimuthu et al. 2010] used DBN’s to model temporal relationships between insulin
and glucose homeostasis. The modeling was further used to predict the future glucose
levels of a patient admitted in an ICU. They also discussed the reasons for using
first-order Markov models to model the temporal relationships. Sandri et al. [Sandri et
al. 2014] used DBNs with multiple order dependencies to impose restrictions on the
causal structure, while modeling organ failure in patients admitted to an ICU. In their
model, each time-stamp represented a day. They further imposed several constraints
such as that no patient discharges were recorded on the second day and that all
patients were either deceased or considered discharged on their seventh day. Such
constraints were imposed to reduce the complexity of the model. Along similar lines,
Rose et al. [Rose et al. 2005] used DBN’s to assist physicians in monitoring the weight
of patients suffering from chronic renal failure, Gatti et al. [Gatti et al. 2011] used it
to model heart failure and Peelen et al. [Peelen et al. 2010] used hierarchical DBN’s
for modeling organ failure. Expectation-Maximization was used to learn conditional
probabilities in these DBN’s.
Sequential Pattern Mining: In the realm of supervised temporal pattern mining,
research has extended the temporal abstraction framework by mining recent temporal
patterns for monitoring and event detection problems in patients suffering from
T2DM [Batal et al. 2012]. Sengupta et al. [Sengupta and Naik 2013] used similar
techniques for detecting sequential rules associated with the early identification of
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brain tumors. Simon et. al. [Simon et al. 2013] proposed survival association rule
mining (SARM) techniques which uses survival modeling techniques to incorporate
the effects of dosage and other confounders such as age and gender.
Deep Learning: Deep Learning has been widely used in conjunction with EHRs
for identification of novel phenotypes and robust clinical decision support systems.
Lasko et al. [Lasko et al. 2013] used deep learning for phenotype discovery in clinical
data. In their analysis, they used a deep learning architecture in conjunction with
Guassian process regression to generate phenotypic features that identified multiple
population subtypes thereby distinguising the uric-acid signatures of acute leukemia
vs gout. They further observed that the phenotypic features were as accurate as
gold standard features created by domain experts. Liang et al. [Liang et al. 2014]
hypothesized that creating effcient feature representations requires massive manual
efforts. To overcome this, they used deep learning based architectures which can
express different complex concept levels with multiple layer networks. They used
deep belief networks for unsupervised feature extraction. Extracted features were
then used to perform supervised learning via SVMs. They observed that their results
deliver the promise associated with deep learning. Miotto et al. [Miotto et al. 2016]
proposed a novel unsupervised feature learning algorithm using three layer stack of
autoencoders that faciliate predictive modeling for various diseases such as T2DM,
cancer and schizophrenia. They observed increased predictive performance when
compared with raw EHR data and traditional feature engineering techniques. Choi
et al. [Choi et al. 2015] used Recurrent Neural Networks to predict the medication
and diagnosis classes for the next visit using longitudinal data consisting of 260K
patients. They further validated their study by validating their results using another
cohort and observed how deep learning based architectures can be used to achieve
better accuracy for noisy and missing clinical data.
Challenges and Limitaitons: These techniques are by far the most successful in
terms of overcoming EHRs related challenges. Right, left and interval based censor-
ing can be easily handled by employing techniques such as Cox proportional hazards
regression and accelerated failure models.
The biggest claim of such techniques is their ability to handle causation. As
these techniques have comparison groups (i.e. case and control) and can handle
time-to-event data, causal analysis can be performed with ease. Further, causation by
adjusting for measured confounders can also be analyzed by using marginal structural
models and structured nested models. However the literature of such techniques in
computer science is very sparse. One area, where more work should be done is to
handle unmeasured confounders for the disease of interest. Similarly more research
needs to be focused in areas where the effects of confounders need to be adjusted for
time-to-event data.
9. Discussion
Despite its infancy, the health care data mining literature is very rich. Table 2, pro-
vides a succinct representation of the major research carried out using data mining
techniques in conjunction with EHRs. For every major application area, presented in
section 2, it lists publications related to the various methodologies from Section 8. In
the rest of this section, we will explore, discuss and present novel insights about how
data mining techniques have been utilized for EHRs. The first three sub-sections cor-
respond to three viewpoints that Table 2 can be viewed from: we can view from the
perspective of the application, the study design and the data mining methodology. In
the fourth and last sub-section, we will discuss what we believe is the most important
barrier to the wide-spread use of data mining in clinical practice.
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Understanding the Natural History of Disease
Descriptive Atemporal [Dunteman 1989; Zhang and Zhang 2002; Cao et al. 2005; Holmes et al. 2011;
Zhang et al. 2014a; Hanauer et al. 2009; Hanauer et al. 2013; Gotz 2016; Gotz
and Stavropoulos 2014; West et al. 2015; Monsen et al. 2010; Monsen et al. 2015]
Descriptive Temporal [Hanauer and Ramakrishnan 2013; Liao and Chen 2013; Hripcsak 2013; Sac-
chi et al. 2007; Jin et al. 2008; Batal et al. 2009; Patnaik et al. 2011; Munson et
al. 2014]
Cross-Sectional [Dasgupta and Chawla 2014; Albers and Hripcsak 2010; Albers and Hripcsak
2012]
Time Agnostic Case-Control or Cohort
Time Aware Case-Control or Cohort [Nachimuthu et al. 2010; Verduijn et al. 2007; Batal et al. 2012; Choi et al. 2016;
Perotte and Hripcsak 2013]
Cohort Identification
Descriptive Atemporal [Roque et al. 2011; Bauer-Mehren et al. 2013]
Descriptive Temporal [Gotz et al. 2014; Schulam et al. 2015; Lasko et al. 2013; Wang et al. 2015a]
Cross-Sectional [Wang et al. 2013b; Peissig et al. 2012; Pathak et al. 2012; Nadkarni et al. 2014;
Chen et al. 2015; Chen et al. 2016; Hripcsak et al. 1997; Hripcsak and Albers
2013]
Time Agnostic Case-Control or Cohort [Carroll et al. 2011; Xu et al. 2011a; Sarvestani et al. 2010]
Time Aware Case-Control or Cohort [Albers et al. 2014; Liu et al. 2015; Che et al. 2015; Albers et al. 2014]
Risk Prediction/Biomarker Discovery
Descriptive Atemporal [Gotz et al. 2011a; Vellanki et al. 2014; Miotto et al. 2016]
Descriptive Temporal
Cross-Sectional [Wilcox and Hripcsak 2003; Sarkar et al. 2012; Letham et al. 2013; Ebadol-
lahi et al. 2010; Feldman and Chawla 2014; Stiglic et al. 2015; Ngufor et al.
2015; Byrd et al. 2014; Liang et al. 2014]
Time Agnostic Case-Control or Cohort [Lin and Haug 2008; Yadav et al. 2016b; Westra et al. 2011; Skevofilakas et al.
2010; Oztekin et al. 2009; Ghalwash and Obradovic ; Somanchi et al. 2015; Li et
al. 2016a; Li et al. 2016b; Li et al. 2016c; Cheng et al. 2016; Collins et al. 2011;
Simon et al. 2011a; Mani et al. 2014; Matheny et al. 2010; Pakhomov et al. 2011;
Fung et al. 2008; Wells et al. 2008; Vinzamuri et al. 2014; Li et al. 2015; van der
Heijden et al. 2014; Jackson et al. 2011; Paxton et al. 2013; Zhao et al. 2011;
Maroco et al. 2011; Breault et al. 2002; Wang et al. 2015b; Sun et al. 2014]
Time Aware Case-Control or Cohort [Wang et al. 2014b; Ghassempour et al. 2014; Yadav et al. 2015b; Gatti et al.
2011; Sandri et al. 2014; Vinzamuri and Reddy 2013; Peelen et al. 2010; Choi
et al. 2015; Wang et al. 2013a; Luo et al. 2016; Hripcsak et al. 2015; Hagar et
al. 2014]
Quantifying the effect of Intervention
Descriptive Atemporal
Descriptive Temporal
Cross-Sectional
Time Agnostic Case-Control or Cohort [Schrom et al. 2013; Westra et al. 2017; Yadav et al. 2016a]
Time Aware Case-Control or Cohort
Constructing evidence based guidelines
Descriptive Atemporal
Descriptive Temporal [Pivovarov et al. 2014]
Cross-Sectional
Time Agnostic Case-Control or Cohort mani2007learning,pruinelli2016data
Time Aware Case-Control or Cohort
Adverse Event Detection
Descriptive Atemporal
Descriptive Temporal
Cross-Sectional [Sathyanarayana et al. 2014; White et al. 2013; Iyer et al. 2014; Haerian et al.
2012; Pathak et al. 2013; Carroll et al. 2011; Xu et al. 2011a; Bobo et al. 2014;
Zhang et al. 2015; Melton and Hripcsak 2005]
Time Agnostic Case-Control or Cohort
Time Aware Case-Control or Cohort hauskrecht2013outlie
Table II: Data Mining Research in EHRs
9.1. Applications
The most popular application for healthcare data mining is risk prediction, followed
by research aimed at understanding the natural history of disease.
The goal of risk prediction is to compute the probability of a patient’s progression to
an outcome (e.g. T2DM) of interest. The reason for its popularity is that it is simply
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the most natural and immediately impactful application. With numerous data mining
and statistical tools and techniques readily available, such analyses can be performed
with ease. The literature using such analyses is rich, providing researchers with op-
portunities to compare their findings.
Another popular application area is understanding the natural history of the dis-
ease. Again, understanding the prevalence, incidence and coincidence of diseases is the
foundation on which policy decisions can be made and thus disciplines like epidemiol-
ogy have spent considerable effort on this application. Also, off-the-shelf statistical or
data mining software, make these studies accessible to a wide range of researchers.
Conversely, certain application areas are virtually unexplored. We found three major
reasons for this: 1) these applications may be technically difficult, requiring knowledge
of concepts that are not commonly known in data mining; 2) they require extensive
collaborations; or 3) the applications in question are simply not practical.
Quantifying the effect of interventions embodies the first reason: it is technically dif-
ficult. It requires two key technical elements that are not usually part of the standard
data mining toolbox: study design and causal inference. On the surface, quantifying
the effect of interventions, say the effect of a drug on an outcome, is a simple causal
inference problem that we described earlier in the survey and some of the solutions,
such as propensity score matching, appear directly applicable. However, a number of
epidemiological considerations are necessary to arrive at a valid conclusion. First, we
need to consider the comparison groups. In a population, there are two groups of pa-
tients: those who are subject to the intervention and those who are not. Clearly, pa-
tients who are subject to the intervention form our exposed group, but who are the
controls (the unexposed group)? Patients who are not subject to the intervention are
of many kinds: patients with no intervention at all; patients who require a weaker in-
tervention; patients who are subject to an alternative, equally effective intervention;
and patients who have already progressed and require a stronger intervention. These
groups could all serve as controls, but depending on which group we choose, we an-
swer a different clinical question. For example, if we are interested in the reduction of
mortality as a result of starting patients on a first-line drug earlier, then our control
group should consist of patients who are not taking any drugs for the same disease;
if we are interested in the reduction of side effect by using a particular drug over the
standard treatment, then the control group should consist of patients who take an
equally effective alternative drug. Propensity score matching alone does not prevent
us from selecting patients from the wrong control group, because comparable patients
may exist in all of the above groups.
Second, how much exposure is sufficient? For many interventions, relatively long
exposure periods are needed to achieve the desired effect. Requiring a certain expo-
sure period, e.g. we only consider patients with 180 days of exposure, introduces bias
(known as immortality bias), because patients who did not tolerate the drug or died
within 180 days are not included, potentially leading to an overly optimistic estimate
for the effect of the intervention.
The second reason for the unpopularity of certain applications is their need for ex-
tensive collaborations. For example, constructing (or even just evaluating) evidence
based guidelines requires more than just a study design and causal inference; it is
decidedly interdisciplinary often critically depending on interpretation and feedback
from researchers with a broad spectrum of clinical expertise. To give a concrete exam-
ple, consider the National Comprehensive Cancer Network guidelines for metastatic
colon cancer: ”Evidence increasingly suggests that [...] mutation makes response to
[...], as single agents or in combination with cytotoxic chemotherapy, highly unlikely.”
This guideline neither requires nor prohibits the use of certain agents when a specific
mutation is present; it merely draws attention to the possibility that the agent may
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not work. Such guidelines leave a lot of room for interpretation: do we administer the
referenced drug or select a different one? Another example is the Surviving Sepsis
Campaign 3-hr bundle. This bundle gives a list of actions, such as ”administer broad
spectrum antibiotics”, that needs to be carried out within 3 hours after the suspicion
of sepsis. This guideline is prescriptive (we know exactly what needs to be done and
when), but even this guideline leaves room for interpretation through the ”suspicion
of sepsis” phrase: we need to estimate when a well-trained clinical would ”suspect”
sepsis.
The third reason for applications being unpopular is that they are unnatural. Ex-
amples include the usage of descriptive data mining techniques for predicting compli-
cations, quantifying the effect of interventions and adverse event detection. Patients
are already grouped into cases and controls and therefore case-control, retrospective
or cross-sectional studies design would be a much more natural choice.
9.2. Study Designs
Substantially more work has been carried out in retrospective or case-control set-
tings as compared to the descriptive setting. This stems from the nature of research in
the medical domain, as research in medical sciences has hitherto been driven by pre-
defined outcomes. The defining difference between case-control and descriptive designs
is the existence of an outcome.
The outcome provides a focus to the case/control studies, which does not exist in
descriptive studies. The lack of an outcome combined with the high dimensionality and
the associated heterogeneity of EHR data often lead to increased complexity, which
translates to exponentially large number of patterns. If the researchers tune their
algorithm to find a small number of patterns, they tend to be trivial patterns; if they
extract a large number of patterns, those patterns are often redundant and difficult to
interpret. Developing algorithms to directly discover novel patterns is an avenue for
method development.
A well-chosen study design with appropriate comparison groups can help address
this problem. Consider, for example, the difference between the retrospective case-
control and cohort study. In case of the case-control design, we select cases (patients
with the outcome in question) and controls (patients without the outcome in question)
at the end of the study and follow them backwards in time examining their exposures.
If the outcome is rare, this approach helps focus on a relatively small population. Ex-
posures associated with the outcome are likely to be present in this smaller population
in sufficient amounts, while ”random” (unassociated) outcomes are reduced. With re-
duced ”random” exposures, we can substantially reduce the number of uninteresting
patterns. Conversely, if the exposure is rare (relative to the outcome), we would select
a cohort study, where patients are selected based on their exposures at baseline and
followed forward in time to see whether they develop the outcome in question. The
rareness of the exposure will control the number of spurious patterns.
9.3. Methodologies
Little research has been done to utilize the temporality associated with EHR data.
For example, descriptive atemporal studies are more frequently conducted as com-
pared to descriptive temporal techniques. The case is similar with retrospective or
case-control studies. We identify a couple of reasons for this phenomenon. First, the
duration of EHR data available with healthcare providers rarely exceeds couple of
years. Diseases such as T2DM take around 5-10 years for patients to progress from
one state to a state of advanced complication. With such a limited duration of data
available, this progression cannot be studied effectively. Secondly, censoring and ir-
regular EHR data limits the application of techniques to EHR data often requiring
sophisticated techniques (such as those from Section 7.2) and rigorous study designs.
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The prevalent method of representing irregular time series data is to add multiple
observations per patient to the observation matrix. Doing so violates the i.i.d. (inde-
pendent and identically distributed) assumption of observations, making them corre-
lated. Section 7.2. describes a number of techniques for addressing this correlation,
but a careful look at these techniques reveals that they are all regression models. The
most popular data mining techniques (SVM, random forests, neural networks) are not
capable of handling this situation satisfactorily without modification. Simply ignor-
ing the correlation could result in reasonable estimates if the number of observations
are similar across the population. In health care, however, this is rarely the case: sick
patients contribute much more data (more frequent visits, more tests per visit) than
relatively healthy patients. Ignoring correlation among observations here will lead to
biased estimates (a form of sampling bias).
To make matters worse, many of these techniques use validation (e.g. leave-out val-
idation) to avoid or reduce overfitting: performance on a leave-out validation set often
serves as the stopping criterion for tree induction. The sampling unit for these tech-
niques is typically each row of the observation matrix. When the rows are observations
of a number of patients, the sampling unit has to be the patient (not the observation).
Therefore, all observations of the same patient must either be in the training set or
the validation set; we cannot have some observations in the training set and others in
the validation set. Failing to follow this rule can lead to overfitting.
9.4. Barriers to Clinical Data Mining
This survey is a testament to the effort that the data mining community has ex-
pended on mining EHR data, yet the translation of these results into clinical practice
is lagging. This lag is a direct consequence of what the authors of this survey view as
the key difference between clinical data mining and data mining in general: clinical
data mining models have to be validated to a standard that is much higher than in
many other fields. Many fields, recommendation systems for example, ”only” require
that we demonstrate a reproducible performance advantage of the proposed model over
the models in use. This standard of validation can be satisfied relatively easily through
textbook validation techniques such as cross-validation, leave-out validation, etc. Va-
lidity in health care often presumes that the model captures some knowledge of human
physiology and pathophysiology. Without using predictors rooted in (patho-)physiology
for clinical prediction, we run the risk of capturing a factor that may change at any
time, invalidating a model that appears to produce computationally reproducible re-
sults. A prototypical example of this phenomenon is the Google Flu Trend that used
queries related to influenza originating from a particular geographic region to assess
the level of exposure to influenza in that region. As a result of changes in user query
behavior, the model became invalid and this service is no longer offered.
With recent advances in machine learning (e.g. deep learning), understanding a
model’s decision process is becoming increasingly difficult. As the recent Workshop
on Human Interpretability of Machine Learning (ICML 2016) shows, health care is
not the only field that desires an understanding of the decision process of the machine
learned models. A paper by Lipton [Lipton 2016] draws a parallel between model in-
terpretability and trusthworthiness and describes several criteria for a trustworthy
model. Constructing trustworthy models is one direction that can help remove barri-
ers from the implementation of machine learned models in clinical practice.
10. Concluding Remarks
The current landscape of health care and the drivers that shape it virtually ensure
that mining EHR data will play an increasingly important role in the future. Major ex-
amples of these drivers include the transition from the current reimbursement-based
health care model to the Accountable Care Organization model; personalizing care to
make it safer, more efficient and to reduce waste; and shared decision making, pa-
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tients’ desire to become more involved in their own care. All of these drivers require
strong analytics based on large populations to be successful.
The cornerstone of modern medicine is clinical evidence and generating hypothe-
ses for clinical evidence is one role that data mining is likely to play. This role is not
a replacement of clinical trials but a synergistic role, where data mining can create
high-quality hypotheses that can be validated through clinical trials. Clinical trials
are expensive, thus the number of patients participating in a study is kept to the min-
imum required to validate the hypothesis. Secondary use of such small data sets for
hypothesis generation is impractical, creating an opportunity for mining EHR data.
Even before the broad availability of EHR-based clinical data, large-scale observa-
tional studies over entire populations have been carried out. However, these studies
have typically utilized claims data, which exhibit many of the key characteristics of
EHR data, including the intermittent generation of longitudinal data, censoring, con-
founding and the need for a robust study design. Methods utilized for these studies
came from biostatistics and epidemiology. The integration of biostatistics techniques
into clinical data mining has already started and novel extensions to biostatistics tech-
niques using data mining are being proposed. Similar, interchange of ideas with epi-
demiology needs to happen but is in an early stage.
EHR data mining to reach its full potential needs to develop them further in many
directions. One of these directions is data representation. EHR data is rich, it consists
of highly heterogeneous data, collected from a wide range of sources (structured and
unstructured clinical data, images, omics data, wearable sensors, mobile health) po-
tentially longitudinally at varying frequencies and resolution. The emergence of such
data type heterogeneity necessitates that we revisit even fundamental questions like
how data is best represented for modeling purposes. Other directions include analyz-
ing temporal and sequence data, handling missing data, and causal inference. Both
data mining and biostatistics/epidemiology have methods to address these issues but
they need to be further developed to suit EHR data better.
The characteristics of EHR data that drive the development of new data mining
techniques are not unique to EHR data. Heterogeneity is present and poses challenges
in many areas, including earth science and climate; time-to-event data finds its
origins in failure analysis; and censoring along with the intermittent interactions
with customers also happens in customer relationship management and recommen-
dation systems. Mirroring how techniques for censored data and causal inference
are being adopted from biostatistics and epidemiology into clinical data mining, new
developments in EHR mining will likely find applications in many other data mining
and analytics domains.
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